Insider Selling: Clearmind Medicine (NASDAQ:CMND) Major Shareholder Sells $27,022.92 in Stock

Clearmind Medicine Inc. (NASDAQ:CMND) major shareholder Financial Lp Hrt sold 225,191 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $0.12, for a total value of $27,022.92. Following the transaction, the insider directly owned 1,838,075 shares of the company’s stock, valued at $220,569. The trade was a 10.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, June 10th, Financial Lp Hrt acquired 2,159,052 shares of Clearmind Medicine stock. The shares were acquired at an average cost of $0.15 per share, with a total value of $323,857.80.

Clearmind Medicine Stock Performance

Shares of NASDAQ CMND opened at $3.34 on Monday. The business has a 50-day moving average of $6.22 and a 200-day moving average of $16.48. The firm has a market capitalization of $3.41 million, a price-to-earnings ratio of -0.02 and a beta of 0.65. Clearmind Medicine Inc. has a 12 month low of $2.10 and a 12 month high of $524.00.

Clearmind Medicine (NASDAQ:CMND) last released its earnings results on Thursday, March 12th. The company reported ($33.20) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Clearmind Medicine to a “sell” rating in a research report on Saturday, May 23rd.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.